Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Portfolio Pulse from Lisa Levin
Several stocks recorded significant movements in Monday's pre-market trading session. Acumen Pharmaceuticals, argenx SE, BridgeBio Pharma, Zai Lab Limited, Lilium N.V., TeraWulf Inc., Quantum-Si incorporated, Immunovant, MorphoSys AG, and Activision Blizzard all saw changes in their share prices. Notably, Activision Blizzard's shares gained 4.3% after Sony and Microsoft Corp reached a 10-year deal to keep 'Call of Duty' games on PlayStation consoles.
July 17, 2023 | 11:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acumen Pharmaceuticals shares jumped 43.9% in pre-market trading after presenting topline results from Phase 1 study of ACU193 for early Alzheimer's disease.
The significant jump in Acumen's share price is likely due to the positive results from their Phase 1 study, which investors may see as a sign of potential future success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
argenx SE shares gained 24.3% in pre-market trading after reporting topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy.
argenx's share price increase is likely due to the positive topline data from their ADHERE study, which investors may interpret as a positive sign for the company's future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Activision Blizzard shares gained 4.3% in pre-market trading after Sony and Microsoft Corp reached a 10-year deal to keep 'Call of Duty' games on PlayStation consoles.
The increase in Activision Blizzard's share price is likely due to the 10-year deal with Sony and Microsoft, which ensures the continued presence of 'Call of Duty' games on PlayStation consoles, a positive development for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100